CA2448246A1 - Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia - Google Patents

Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia Download PDF

Info

Publication number
CA2448246A1
CA2448246A1 CA002448246A CA2448246A CA2448246A1 CA 2448246 A1 CA2448246 A1 CA 2448246A1 CA 002448246 A CA002448246 A CA 002448246A CA 2448246 A CA2448246 A CA 2448246A CA 2448246 A1 CA2448246 A1 CA 2448246A1
Authority
CA
Canada
Prior art keywords
stress
carnitine
acetyl
rats
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002448246A
Other languages
English (en)
French (fr)
Inventor
Menotti Calvani
Luigi Mosconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001RM000292A external-priority patent/ITRM20010292A1/it
Priority claimed from IT2001RM000319A external-priority patent/ITRM20010319A1/it
Application filed by Individual filed Critical Individual
Publication of CA2448246A1 publication Critical patent/CA2448246A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002448246A 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia Abandoned CA2448246A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT2001RM000292A ITRM20010292A1 (it) 2001-05-29 2001-05-29 Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
ITRM2001A000292 2001-05-29
IT2001RM000319A ITRM20010319A1 (it) 2001-06-08 2001-06-08 Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.
ITRM2001A000319 2001-06-08
PCT/IT2002/000339 WO2002096411A1 (en) 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Publications (1)

Publication Number Publication Date
CA2448246A1 true CA2448246A1 (en) 2002-12-05

Family

ID=26332845

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002448246A Abandoned CA2448246A1 (en) 2001-05-29 2002-05-24 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia

Country Status (16)

Country Link
US (2) US20040171685A1 (https=)
EP (1) EP1399143B1 (https=)
JP (1) JP2004532867A (https=)
KR (1) KR20040003031A (https=)
AT (1) ATE345124T1 (https=)
CA (1) CA2448246A1 (https=)
CZ (1) CZ20033222A3 (https=)
DE (1) DE60216090T2 (https=)
DK (1) DK1399143T3 (https=)
ES (1) ES2275881T3 (https=)
HU (1) HUP0400007A2 (https=)
MX (1) MXPA03010920A (https=)
PL (1) PL367628A1 (https=)
PT (1) PT1399143E (https=)
SK (1) SK15862003A3 (https=)
WO (1) WO2002096411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
CA3238205A1 (en) 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani

Also Published As

Publication number Publication date
CZ20033222A3 (cs) 2004-06-16
ATE345124T1 (de) 2006-12-15
ES2275881T3 (es) 2007-06-16
US20060148896A1 (en) 2006-07-06
DE60216090D1 (de) 2006-12-28
DK1399143T3 (da) 2007-03-26
WO2002096411A1 (en) 2002-12-05
KR20040003031A (ko) 2004-01-07
PL367628A1 (en) 2005-03-07
EP1399143A1 (en) 2004-03-24
HUP0400007A2 (hu) 2004-04-28
SK15862003A3 (sk) 2004-06-08
US20040171685A1 (en) 2004-09-02
DE60216090T2 (de) 2007-05-31
EP1399143B1 (en) 2006-11-15
MXPA03010920A (es) 2004-02-27
JP2004532867A (ja) 2004-10-28
PT1399143E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
US6335361B1 (en) Method of treating benign forgetfulness
EP2135606A1 (en) Anti-fatigue agent
MXPA00012808A (es) El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva.
US4397866A (en) Process for increasing glycine levels in the brain and spinal cord
Schildkraut Pharmacology—the effects of lithium on biogenic amines
HUP0004336A2 (hu) Készítmény alkoholistákban fellépő megvonási tünetek és alkohol iránti ellenállhatatlan szükségérzet elnyomására és az alkohol túlzott mértékű fogyasztásának megelőzésére egészséges alanyokban
EP1399143B1 (en) Use of acetyl l-carnitine for the preparation of a medication to treat anhedonia
EP1784177B1 (de) Formulierung für l-tryptophan mit carbidopa/ benserazid
Silk Branched chain amino acids in liver disease: fact or fantasy?
KR102722498B1 (ko) 인지 기능 개선용 조성물 및 불안양 증상 개선용 조성물, 및 뇌 위축 억제용 조성물
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
US20020077349A1 (en) Method of treating age-related vision impairment
EP3071197B1 (en) Food for special medical purposes or food supplement formulation for treating hearing disturbances
Brot et al. Flavor, not postingestive, cues contribute to the salience of proteins as targets in aversion conditioning.
Şahin et al. Impairment of motor coordination in mice after ingestion of aluminum chloride
US8013016B2 (en) Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome
EP0344158A1 (de) Schmerzpräparat.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued